Literature DB >> 21757169

Assessment of coronary atherosclerosis progression and regression at bifurcations using combined IVUS and OCT.

Roberto Diletti1, Hector M Garcia-Garcia, Josep Gomez-Lara, Salvatore Brugaletta, Joanna J Wykrzykowska, Nienke van Ditzhuijzen, Robert Jan van Geuns, Evelyn Regar, Giuseppe Ambrosio, Patrick W Serruys.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the progression of atherosclerotic coronary plaques at bifurcations, using combined intravascular ultrasound-virtual histology (IVUS-VH) and optical coherence tomography (OCT).
BACKGROUND: Pathological findings reveal that atherosclerotic plaques characterized by the presence of large necrotic cores (NCs) with fibrous cap thicknesses < 65 μm are more prone to rupture. Accuracy in the detection of high-risk plaques could be improved by the combined use of IVUS-VH and OCT.
METHODS: IVUS-VH and OCT are 2 imaging modalities with different lateral resolutions and different depths of penetration. To provide a precise matching of the images, bifurcations were used as landmarks. IVUS-VH and OCT were performed in 56 bifurcations from 24 patients at baseline and at 6-month follow-up. All patients were treated with standard medical therapy. Bifurcations were studied at the proximal, in-bifurcation, and distal regions. Plaques were classified according to their composition as assessed by IVUS-VH and fibrous cap thickness as quantified by OCT.
RESULTS: At baseline, 27 NC-rich plaques were found. At 6-month follow-up, 22 (81%) did not show any significant change. Four new NC-rich lesions developed. At both time points, percent NC was higher and the fibrous cap was thinner at the proximal bifurcation rim compared with the distal. There were no significant changes in percent NC and fibrous cap thickness in the 3 bifurcation regions between baseline and follow-up examinations. No major cardiovascular events due to bifurcation lesion progression were observed.
CONCLUSIONS: The combined use of IVUS-VH and OCT is a reliable tool to serially assess plaque progression and regression, and in the present study it was demonstrated to be safe and feasible. At 6-month follow-up, in this post-percutaneous coronary intervention patient population, most high-risk plaques remained unchanged, retaining their imaging classifications, nevertheless appearing to have remained clinically silent.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21757169     DOI: 10.1016/j.jcmg.2011.04.007

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  8 in total

Review 1.  Non-ST-segment elevation acute coronary syndromes: targeted imaging to refine upstream risk stratification.

Authors:  Henry Chang; James K Min; Sunil V Rao; Manesh R Patel; Orlando P Simonetti; Giuseppe Ambrosio; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2012-07       Impact factor: 7.792

2.  Comparison of longitudinal geometric measurement in human coronary arteries between frequency-domain optical coherence tomography and intravascular ultrasound.

Authors:  Yong Liu; Kunihiro Shimamura; Takashi Kubo; Atsuhi Tanaka; Hironori Kitabata; Yasushi Ino; Takashi Tanimoto; Yasutsugu Shiono; Makoto Orii; Takashi Yamano; Tomoyuki Yamaguchi; Kumiko Hirata; Toshio Imanishi; Takashi Akasaka
Journal:  Int J Cardiovasc Imaging       Date:  2013-11-24       Impact factor: 2.357

3.  Factors Associated With Coronary Artery Disease Progression Assessed By Serial Coronary Computed Tomography Angiography.

Authors:  Gabriel Cordeiro Camargo; Tamara Rothstein; Maria Eduarda Derenne; Leticia Sabioni; João A C Lima; Ronaldo de Souza Leão Lima; Ilan Gottlieb
Journal:  Arq Bras Cardiol       Date:  2017-05-04       Impact factor: 2.000

4.  Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.

Authors:  Yaping Zeng; Rafael Cavalcante; Erhan Tenekecioglu; Pannipa Suwannasom; Yohei Sotomi; Carlos Collet; Mahammad Abdelghani; Hans Jonker; Franck Digne; Dieter Horstkotte; Manfred Zehender; Ciro Indolfi; Francesco Saia; Rosario Fiorilli; Bernard Chevalier; Leonardo Bolognese; Javier Goicolea; Shaoping Nie; Yoshinobu Onuma; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2016-12-23       Impact factor: 2.357

5.  Impact of combined plaque structural stress and wall shear stress on coronary plaque progression, regression, and changes in composition.

Authors:  Charis Costopoulos; Lucas H Timmins; Yuan Huang; Olivia Y Hung; David S Molony; Adam J Brown; Emily L Davis; Zhongzhao Teng; Jonathan H Gillard; Habib Samady; Martin R Bennett
Journal:  Eur Heart J       Date:  2019-05-07       Impact factor: 29.983

Review 6.  Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque.

Authors:  Nataliya V Mushenkova; Volha I Summerhill; Dongwei Zhang; Elena B Romanenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

7.  Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study.

Authors:  Il Soo Lee; Christos V Bourantas; Takashi Muramatsu; Bill D Gogas; Jung Ho Heo; Roberto Diletti; Vasim Farooq; Yaojun Zhang; Yoshinobu Onuma; Patrick W Serruys; Hector M Garcia-Garcia
Journal:  Cardiovasc Ultrasound       Date:  2013-07-20       Impact factor: 2.062

8.  Translation of atherosclerotic plaque phase-contrast CT imaging from synchrotron radiation to a conventional lab-based X-ray source.

Authors:  Tobias Saam; Julia Herzen; Holger Hetterich; Sandra Fill; Marian Willner; Marco Stockmar; Klaus Achterhold; Irene Zanette; Timm Weitkamp; Ulrich Schüller; Sigrid Auweter; Silvia Adam-Neumair; Konstantin Nikolaou; Maximilian F Reiser; Franz Pfeiffer; Fabian Bamberg
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.